ZNF224

Summary

ZNF224 (zinc finger protein 224, HGNC:13017) is a protein-coding gene on chromosome 19q13.31, encoding Zinc finger protein 224 (Q9NZL3). May be involved in transcriptional regulation as a transcriptional repressor.

This gene encodes a member of the Krueppel C2H2-type zinc-finger family of proteins. The encoded protein represses transcription of the aldolase A gene, which encodes a key enzyme in glycolysis. The encoded zinc-finger protein may also function as a transcriptional co-activator with Wilms’ tumor protein 1 to regulate apoptotic genes in leukemia.

Source: NCBI Gene 7767 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 120 total
• MANE Select transcript: NM_001321645

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13017
Approved symbol	ZNF224
Name	zinc finger protein 224
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	BMZF-2, KOX22
Ensembl gene	ENSG00000267680
Ensembl biotype	protein_coding
OMIM	194555
Entrez	7767

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000336976, ENST00000586978, ENST00000589060, ENST00000589870, ENST00000590614, ENST00000591511, ENST00000591551, ENST00000684943, ENST00000693561, ENST00000902928, ENST00000902929, ENST00000950453, ENST00000950454

RefSeq mRNA: 2 — MANE Select: NM_001321645 NM_001321645, NM_013398

CCDS: CCDS33046

Canonical transcript exons

ENST00000693561 — 6 exons

Exon	Start	End
ENSE00001345463	44096343	44096431
ENSE00002497952	44100801	44100927
ENSE00002726170	44101133	44101225
ENSE00002852050	44094361	44094530
ENSE00003487786	44097806	44097888
ENSE00003936016	44106396	44109826

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 91.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.8788 / max 157.8898, expressed in 1610 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
176245	2.6586	1218
176246	2.4314	1308
176247	0.7887	521

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar hemisphere	UBERON:0002245	91.06	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.98	gold quality
cerebellar cortex	UBERON:0002129	90.93	gold quality
rectum	UBERON:0001052	90.44	gold quality
mucosa of stomach	UBERON:0001199	90.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.18	gold quality
right uterine tube	UBERON:0001302	90.08	gold quality
cerebellum	UBERON:0002037	89.72	gold quality
left ovary	UBERON:0002119	89.65	gold quality
spleen	UBERON:0002106	89.18	gold quality
left lobe of thyroid gland	UBERON:0001120	89.12	gold quality
right ovary	UBERON:0002118	88.96	gold quality
right lobe of thyroid gland	UBERON:0001119	88.81	gold quality
right lung	UBERON:0002167	88.74	gold quality
apex of heart	UBERON:0002098	88.72	gold quality
thyroid gland	UBERON:0002046	88.63	gold quality
tendon of biceps brachii	UBERON:0008188	88.61	gold quality
small intestine	UBERON:0002108	88.58	gold quality
metanephros cortex	UBERON:0010533	88.52	gold quality
lymph node	UBERON:0000029	88.33	gold quality
sural nerve	UBERON:0015488	88.22	gold quality
adenohypophysis	UBERON:0002196	88.19	gold quality
body of pancreas	UBERON:0001150	88.16	gold quality
body of uterus	UBERON:0009853	88.07	gold quality
descending thoracic aorta	UBERON:0002345	87.97	gold quality
pituitary gland	UBERON:0000007	87.72	gold quality
ovary	UBERON:0000992	87.70	gold quality
right adrenal gland cortex	UBERON:0035827	87.62	gold quality
minor salivary gland	UBERON:0001830	87.60	gold quality
granulocyte	CL:0000094	87.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.08

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
ALDOA	Repression
SLC25A1	Unknown
VDR	Activation

miRNA regulators (miRDB)

92 targeting ZNF224, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805

Literature-anchored findings (GeneRIF, showing 16)

• Results suggest that bone marrow zinc finger 2 (BMZF2) interferes with the transactivation potential of Wilms tumor suppressor gene (WT1). (PMID:12239212)
• We demonstrate that ZNF224, a Kruppel-like zinc finger transcription factor, is the repressor protein that specifically binds to the negative cis-element AldA-NRE and affects the AldA-NRE-mediated transcription (PMID:12527367)
• Differential expression and cellular localization of ZNF224 and ZNF255, two isoforms of the Kruppel-like zinc-finger protein family. (PMID:17900823)
• CIC silencer activity extends over 26 bp (-595/-569), which specifically bind a protein ZNF224 present in HepG2 cell nuclear extracts. (PMID:19505435)
• ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene (PMID:19741270)
• Coimmunoprecipitation and immunocytochemistry revealed that DEPDC1 interacted and colocalized with zinc finger transcription factor ZNF224, a known transcriptional repressor. (PMID:20587513)
• ZNF224 acts as a transcriptional co-regulator of WT1. (PMID:20591825)
• REVIEW: ZNF224 is a multifunctional protein and alternative splicing, sub-cellular compartmentalization and isoform-specific interactions may modulate its activity (PMID:21187159)
• ZNF224 acts in fine tuning of WT1-dependent control of gene expression, acting as a co-activator of WT1 in the regulation of proapoptotic genes and suppressing WT1 mediated transactivation of antiapoptotitc genes. (PMID:23362234)
• Data show that Wilms’ tumor 1 protein (WT1)binds to the zinc finger protein 224 (ZNF224) promoter and represses ZNF224 expression. (PMID:26320177)
• The analyses using human breast ductal carcinoma tissues exhibited that the expression of ZNF224 and miR-663a was increased in cancer compared to non-cancer region. (PMID:27105517)
• we showed that ZNF224 positively modulates cyclin D3 gene expression. Consistently, we observed that alteration of ZNF224 expression leads to defects in cell cycle control. All together, our results strongly suggest that in Chronic lymphocytic leukaemia (CLL)cells high expression level of ZNF224 can lead to inappropriate cell growth and apoptosis resistance, thus contributing to CLL progression (PMID:28040726)
• Increasing information on the mechanism through which ZNF224 can operate could lead to the identification of agents capable of modulating ZNF224 function, thus potentially paving the way to new therapeutic strategies for treatment of cancer (PMID:28215224)
• identify the receptor tyrosine kinase Axl as a novel target of ZNF224 transcriptional repression activity. (PMID:30176265)
• ZNF224 is a mediator of TGF-beta pro-oncogenic function in melanoma. (PMID:34181020)
• ZNF224 Protein: Multifaceted Functions Based on Its Molecular Partners. (PMID:34684876)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 224 — Q9NZL3 (reviewed: Q9NZL3)

Alternative names: Bone marrow zinc finger 2, Zinc finger protein 233, Zinc finger protein 255, Zinc finger protein 27, Zinc finger protein KOX22

All UniProt accessions (3): Q9NZL3, K7EL24, K7ENI7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation as a transcriptional repressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells.

Subunit / interactions. Interacts with WT1. Interacts with DEPDC1A.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous. Mainly expressed in fetal tissues.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001308574, NP_037530 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (97 total): strand 34, helix 21, zinc finger region 18, turn 8, sequence variant 6, sequence conflict 6, cross-link 2, chain 1, domain 1

Structure

Experimental structures (PDB)

16 structures.

PDB	Method	Resolution (Å)
2ELY	SOLUTION NMR
2ELZ	SOLUTION NMR
2EM0	SOLUTION NMR
2EM6	SOLUTION NMR
2EM7	SOLUTION NMR
2EM8	SOLUTION NMR
2EM9	SOLUTION NMR
2EN1	SOLUTION NMR
2EN8	SOLUTION NMR
2ENA	SOLUTION NMR
2ENC	SOLUTION NMR
2EOQ	SOLUTION NMR
2EOR	SOLUTION NMR
2EQ4	SOLUTION NMR
2YSP	SOLUTION NMR
2YTH	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NZL3-F1	70.87	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 473, 625

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway
R-HSA-9843940	Regulation of endogenous retroelements by KRAB-ZFP proteins

MSigDB gene sets: 78 (showing top): MODULE_480, MODULE_427, GOCC_NUCLEAR_ENVELOPE, GOCC_TRANSCRIPTION_REPRESSOR_COMPLEX, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, GOCC_NUCLEAR_MEMBRANE, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOCC_ORGANELLE_ENVELOPE, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, OISHI_CHOLANGIOMA_STEM_CELL_LIKE_UP, GOMF_DNA_BINDING_TRANSCRIPTION_REPRESSOR_ACTIVITY, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription repressor complex (GO:0017053), nuclear membrane (GO:0031965)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Regulation of endogenous retroelements	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
negative regulation of transcription by RNA polymerase II	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transition metal ion binding	1
DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
transcription regulator complex	1
nucleus	1
nuclear envelope	1
organelle membrane	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

19 interactions, top by confidence:

A	B	Type	Score
FANCL	ZNF224	psi-mi:“MI:0915”(physical association)	0.560
CARD9	ZNF224	psi-mi:“MI:0915”(physical association)	0.560
MAGEA8	ZNF224	psi-mi:“MI:0915”(physical association)	0.560
ZNF224	LRP4	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
MTUS2	ZNF224	psi-mi:“MI:0915”(physical association)	0.370
PB2	SEC15L3	psi-mi:“MI:0914”(association)	0.350
PB2		psi-mi:“MI:0914”(association)	0.350
APP	ZNF224	psi-mi:“MI:0915”(physical association)	0.000
ZNF224	MAGEA8	psi-mi:“MI:0915”(physical association)	0.000
ZNF224	CLIC6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): MTUS2 (Two-hybrid), ZNF224 (Co-fractionation), PTX3 (Affinity Capture-MS), LRP1B (Affinity Capture-MS), LRP4 (Affinity Capture-MS), SORL1 (Affinity Capture-MS), ZNF813 (Affinity Capture-MS), LRP2 (Affinity Capture-MS), NOTCH3 (Affinity Capture-MS), ZNF224 (Synthetic Lethality), ZNF224 (Two-hybrid), SORL1 (Affinity Capture-MS), NOTCH3 (Affinity Capture-MS), TGM3 (Affinity Capture-MS), LRP1B (Affinity Capture-MS)

ESM2 similar proteins: A0JNB1, A1YF12, A1YG88, A2T759, A6QLU5, B2RUI1, D3ZVT0, O14709, O43296, O75123, P10072, P15621, P17020, P17097, P51814, P85977, Q08ER8, Q0VGE8, Q14590, Q32KN0, Q3KQV3, Q4V8A8, Q5CZA5, Q5RBX0, Q5RCD9, Q5VIY5, Q61116, Q61967, Q6GQR8, Q6P9A3, Q6ZMS4, Q7TSH9, Q7TSI0, Q7Z3I7, Q86UD4, Q86WZ6, Q8BFS8, Q8IZ26, Q8N9F8, Q8TAF7

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ZNF224	“down-regulates quantity by repression”	ALDOA	“transcriptional regulation”
ZNF224	“down-regulates quantity by repression”	Aldolase	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	89
Likely benign	13
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

921 predictions. Top by Δscore:

Variant	Effect	Δscore
19:44094522:A:T	donor_gain	1.0000
19:44096327:T:TA	acceptor_gain	1.0000
19:44096330:T:TA	acceptor_gain	1.0000
19:44096333:T:TA	acceptor_gain	1.0000
19:44097793:T:A	acceptor_gain	1.0000
19:44097794:G:A	acceptor_gain	1.0000
19:44100911:G:GT	donor_gain	1.0000
19:44100912:A:T	donor_gain	1.0000
19:44100923:AGTGG:A	donor_loss	1.0000
19:44100924:G:GG	donor_gain	1.0000
19:44100926:GGGTG:G	donor_loss	1.0000
19:44100928:G:C	donor_loss	1.0000
19:44103243:T:G	donor_gain	1.0000
19:44103243:T:TG	donor_gain	1.0000
19:44096292:C:G	acceptor_gain	0.9900
19:44096342:GCT:G	acceptor_gain	0.9900
19:44097797:A:AG	acceptor_gain	0.9900
19:44097798:C:G	acceptor_gain	0.9900
19:44097800:TTGCA:T	acceptor_loss	0.9900
19:44097801:TGCAG:T	acceptor_loss	0.9900
19:44097802:GCA:G	acceptor_loss	0.9900
19:44097803:CA:C	acceptor_loss	0.9900
19:44097804:A:AG	acceptor_gain	0.9900
19:44097805:G:GC	acceptor_loss	0.9900
19:44097805:G:GG	acceptor_gain	0.9900
19:44097805:GGCAC:G	acceptor_gain	0.9900
19:44097859:GAA:G	donor_gain	0.9900
19:44097885:CAAGG:C	donor_loss	0.9900
19:44097887:AG:A	donor_loss	0.9900
19:44097888:GG:G	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000123934 (19:44106044 G>A,T), RS1000517733 (19:44102562 G>A), RS1000612327 (19:44101633 G>A), RS1000745724 (19:44096019 G>A), RS1000747997 (19:44109019 C>T), RS1000992241 (19:44095586 A>C), RS1001055022 (19:44094647 T>G), RS1001185069 (19:44105567 A>T), RS1001411023 (19:44099181 C>G,T), RS1001656313 (19:44098814 G>T), RS1002084430 (19:44101934 T>C), RS1002257518 (19:44097295 A>T), RS1002356557 (19:44095337 A>C,G), RS1002429871 (19:44108443 T>C), RS1002562831 (19:44098163 C>T)

Disease associations

OMIM: gene MIM:194555 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST000310_1	Alzheimer’s disease	2.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
bisphenol A	decreases expression, increases expression	2
Air Pollutants	decreases expression, affects cotreatment, increases abundance, increases oxidation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	affects cotreatment, decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
geraniol	increases expression	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	increases expression	1
cupric oxide	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
bromovanin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation, increases methylation	1
Acetaminophen	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer